Beta Bionics Receives FDA Warning Letter Citing Quality System Deficiencies At California Facility
Benzinga Newsdesk 9 months ago
NewsFDA
On January 29, 2026, Beta Bionics, Inc. (the "Company") received a warning letter (the "Warning Letter") from the U.S. Food and Drug Administration (the "FDA") following inspection of the Company's facility in Irvine,
On January 29, 2026, Beta Bionics, Inc. (the "Company") received a warning letter (the "Warning Letter") from the U.S. Food and Drug Administration (the "FDA") following inspection of the Company's facility in Irvine, California that occurred from June 9, 2025 through June 26, 2025. In the Warning Letter, the FDA cited deficiencies in the response letters sent by the Company to the FDA following the FDA's issuance of a Form 483, List of Investigational Observations (the "Form 483"), which was issued to the Company by the FDA in connection with the aforementioned inspection that took place in June 2025.
The Warning Letter highlights non-conformities observed by the FDA in relation to the Company's Quality Management System, Medical Device Reporting, and Correction and Removals, which were previously communicated by the FDA in the Form 483. The Warning Letter does not restrict the Company's ability to produce, market, manufacture or distribute products, nor restrict the Company's ability to seek FDA 510(k) clearance of new products.
The Company takes the observations described in the Warning Letter seriously, and is currently preparing a written response to the Warning Letter. Several corrective actions have already occurred including improvements to the processes identified in the warning letter. Additional corrective actions may be identified and executed based upon feedback from the FDA provided in the Warning Letter. The Company intends to provide regular updates to the FDA in response to the Form 483 and Warning Letter. However, the Company cannot provide any assurances that the FDA will be satisfied with its response or as to the expected date of the resolution of the matters included in the Warning Letter. Until the deficiencies cited in the Warning Letter are resolved to the FDA's satisfaction, additional legal or regulatory action may be taken without further notice.
The Company does not expect the Warning Letter to materially impact the Company's previously disclosed guidance that it expects to launch the commercialization of Mint by the end of 2027.